Vericel (VCEL) EBITDA (2010 - 2026)
Vericel (VCEL) posted EBITDA of $434000.0 for Q2 2026, up 105.38% sequentially from -$8.1 million in Q1 2026, and up 121.39% YoY from $196034.3 in Q2 2025.
Vericel (VCEL) EBITDA (2010 - 2026) Analysis & Trends
Vericel has reported EBITDA for 17 years, with the latest figure at $434000.0 in Q2 2026.
- Quarterly EBITDA rose 121.39% year-over-year to $434000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.2 million (up 1428.5% YoY) and the FY2025 annual result came in at $11.0 million, up 144.39% from the prior year.
- EBITDA improved to $434000.0 in Q2 2026 per VCEL's latest filing, from -$8.1 million in the prior quarter.
- Over five years, EBITDA peaked at $22.4 million in Q4 2025 and troughed at -$12.8 million in Q1 2025.
- A 5-year average of -$866055.6 and a median of -$5.3 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 143.55% in 2022, then soared 239.96% in 2025.
- Over 5 years, EBITDA stood at $6.1 million in 2022, then surged by 109.22% to $12.7 million in 2023, then soared by 45.15% to $18.5 million in 2024, then rose by 21.3% to $22.4 million in 2025, then slumped by 98.06% to $434000.0 in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $434000.0, -$8.1 million, and $22.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 434,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 434,000.00 |
| Mar 31, 2026 | -8.06 Mn |
| Dec 31, 2025 | 22.42 Mn |
| Sep 30, 2025 | 3.45 Mn |
| Jun 30, 2025 | -2.03 Mn |
| Mar 31, 2025 | -12.79 Mn |
| Dec 31, 2024 | 18.48 Mn |
| Sep 30, 2024 | -2.47 Mn |
| Jun 30, 2024 | -6.03 Mn |
| Mar 31, 2024 | -5.46 Mn |
| Dec 31, 2023 | 12.73 Mn |
| Sep 30, 2023 | -5.06 Mn |
| Jun 30, 2023 | -5.96 Mn |
| Mar 31, 2023 | -8.18 Mn |
| Dec 31, 2022 | 6.09 Mn |
| Sep 30, 2022 | -6.79 Mn |
| Jun 30, 2022 | -9.08 Mn |
| Mar 31, 2022 | -7.27 Mn |
| Dec 31, 2021 | 4.14 Mn |
| Sep 30, 2021 | -4.96 Mn |